Evaluation of a Personcentered Internet-based CBT Program for Stress, Anxiety and Depressive Symptoms in Patients With Cardiovascular Disease

May 7, 2024 updated by: Peter Johansson, University Hospital, Linkoeping

Evaluation of an Adaptable and Personcentered Internet-based CBT Program Aimed to Treat Stress, Anxiety and Depressive Symptoms in Patients With Cardiovascular Disease

To evaluate a nine-week adaptable and person-centred I-CBT program that can be directed towards stress, anxiety and depressive symptoms in persons with CVD.

Study Overview

Detailed Description

All patients diagnosed as CVD (i.e. diagnosis Ischemia (ICD-code I20., I25.), Heart Failure (ICD-code I50., I42.) or Arrhythmia (ICD-code I48, I49, DF016) and who received care in the last 12 months at hospitals in the south-east of Sweden will be contacted by letter with information about the study.

Participants who are interested are invited to visit our website for more information, registration and provision of informed consent. After registration, participants will respond to questions about demographics, medical history, stress, anxiety and depressive symptoms on the website. Inclusion or exclusion will be assessed by a group consisting of a psychologist, cardiology specialist nurse and a psychiatry specialist nurse.

Before final inclusion and randomization eligible participants will be contacted for a telephone interview held by the study nurses.

Included (n=400) participants will, on our website (www.xxxxxx), complete the baseline study questionnaires and then be randomized according to a 2 x2 factorial design.

Study Type

Interventional

Enrollment (Estimated)

400

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

    • Linköpings Universitet
      • Norrköping, Linköpings Universitet, Sweden, 601 74

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • age 18 years and above
  • treatment for cardiovascular disease (CVD) according to European Society of Cardiology guidelines
  • stable CVD (New York Heart Association class I-III) and not having been hospitalised for CVD in in the last four weeks.
  • stress (Perceived Stress Scale (PSS)-10>13 points) and/or
  • anxiety (i.e. General Anxiety Disorder Scale (GAD) ≥5 points) and/or
  • depressive symptoms (Patient Health Questionnaire-9 28 (PHQ-9) > 5 points)

Exclusion Criteria:

  • severe CVD (New York Heart Association classification IV) or another severe chronic life-threatening disease
  • severe stress, anxiety or depression assessed as requiring acute treatment
  • not being able to dedicate 3-4 hours per week to participate in the program

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Factorial Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Design of the CBT treatment content
Patient determined CBT content (i.e. person-centered) vs. therapist determined I-CBT content

When determining the content of the I-CBT program, the participants and therapist will be allowed to choose from a library of treatment modules.

Therapist controlled support and feedback are given weekly and in a structured manner. Participants will be able to contact the therapist when support and feedback is desired

Experimental: Control of support and feedback
Patient-controlled support and feedback (person-centred) vs. therapist -controlled.

When determining the content of the I-CBT program, the participants and therapist will be allowed to choose from a library of treatment modules.

Therapist controlled support and feedback are given weekly and in a structured manner. Participants will be able to contact the therapist when support and feedback is desired

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in stress from baseline to 9 weeks on the 10 item Perceived Stress Scale
Time Frame: From baseline to 9 weeks at the end of the intervention.
The 10-item Perceived Stress Scale is a valideted self-report of Stress. The instreument measures the degree to which individuals perceives their life situations as stressful. The 10 items are rated on a 5 point scale and higher scores means more stress
From baseline to 9 weeks at the end of the intervention.
Change in anxiety from baseline to 9 weeks on the 7-item Generalized Anxiety Disorder Scale.
Time Frame: From baseline to 9 weeks at the end of the intervention.
General Anxiety Disorder scale is validagted self-resport that measure symptoms of general anxiety during the last two weeks. The 7-items range from 0 (not bothered at all) to 3 (nearly every day). A higher score indicate more anxiety and the cut-off 5 suggests at least mild anxiety.
From baseline to 9 weeks at the end of the intervention.
Change in depressive symptoms from baseline to 9 weeks on the 9 item Patient Health Questionnaire.
Time Frame: From baseline to 9 weeks at the end of the intervention.
The 9-item Patient Health Questionnaire is a validated self-report that measure depressive symtpoms during the last two weeks. Each item is answered on a four graded scale where 0 means that the person not is affected and 3 where the person is affected several Days to almost every day. Higher numbers represents higher levels of depressive symptoms. A cut-off >5 represents at least mild depression.
From baseline to 9 weeks at the end of the intervention.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Peter Johansson, Ph.D, Department of Health, Medicine and Caring Sciences, Linkoping University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

March 13, 2023

Primary Completion (Estimated)

July 1, 2025

Study Completion (Estimated)

June 1, 2027

Study Registration Dates

First Submitted

January 22, 2021

First Submitted That Met QC Criteria

January 25, 2021

First Posted (Actual)

January 27, 2021

Study Record Updates

Last Update Posted (Actual)

May 8, 2024

Last Update Submitted That Met QC Criteria

May 7, 2024

Last Verified

May 1, 2024

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

IPD Plan Description

Our university works with the question of we can share IPD without violoating GPDR

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Cardiovascular Disease

Clinical Trials on internet-based cognitive behavioral theraphy

3
Subscribe